Different infusion durations for preventing platinum-induced hearing loss in children with cancer.

@article{As2016DifferentID,
  title={Different infusion durations for preventing platinum-induced hearing loss in children with cancer.},
  author={Jorrit W van As and H. van den Berg and E. C. van Dalen},
  journal={The Cochrane database of systematic reviews},
  year={2016},
  volume={8},
  pages={
          CD010885
        }
}
  • Jorrit W van As, H. van den Berg, E. C. van Dalen
  • Published 2016
  • Medicine
  • The Cochrane database of systematic reviews
    • BACKGROUND Platinum-based therapy, including cisplatin, carboplatin or oxaliplatin, or a combination of these, is used to treat a variety of paediatric malignancies. Unfortunately, one of the most important adverse effects is the occurrence of hearing loss or ototoxicity. In an effort to prevent this ototoxicity, different platinum infusion durations have been studied. This review is an update of a previously published Cochrane review. OBJECTIVES To assess the effects of different durations… CONTINUE READING
    View on PubMed
    cochranelibrary.com
    10 Citations
    Background Citations
    5
    Results Citations
    1
    10 Citations
    Citation Type

    Citation Type

    Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    • 2
    • PDF
    Cochrane corner: platinum-induced hearing loss after treatment for childhood cancer
    • 1
    Pharmacological intervention in the field of ototoxicity
    • 8
    • PDF
    Age-corrected hearing loss after chemoradiation in cervical cancer patients
    • 2
    Carboplatin and vincristine neurotoxicity in the treatment of pediatric low‐grade gliomas
    • 6
    Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
    • 15
    Drug‐induced ototoxicity: Mechanisms, Pharmacogenetics, and protective strategies
    • 74
    The Role of Next Generation Sequencing in the Molecular Diagnosis and Treatment of Retinoblastoma
    • PDF
    Up-regulation of autophagy and apoptosis of cochlear hair cells in mouse models for deafness
    • 1
    • PDF
    Der intervallkorrigierte Hörverlust nach Cisplatin-basierter Radiochemotherapie von Patientinnen mit Zervixkarzinom

    References

    SHOWING 1-10 OF 15 REFERENCES
    Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
    • 1
    Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
    • 63
    Hearing Loss in Pediatric Oncology Patients Receiving Carboplatin-containing Regimens
    • 55
    Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.
    • 361
    • PDF
    Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.
    • 276
    Understanding platinum-induced ototoxicity.
    • 128
    Cisplatin ototoxicity in children: a practical grading system.
    • 249
    Auditory Late Effects of Childhood Cancer Therapy: A Report From the Children's Oncology Group
    • 130
    Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer
    • 156
    Furosemide-induced ototoxicity.
    • 86